Gut markers for metastatic melanoma receiving immunotherapy
Open Access
- 1 July 2025
- journal article
- research article
- Published by Springer Nature in BMC Cancer
- Vol. 25 (1) , 1-13
Abstract
This project aimed to discover independent gut markers of immunotherapy based on qPCR method. 80 metastatic melanoma patients receiving immunotherapy were enrolled in this study, and the relative abundance of 41 gut markers was worked out by a newly established qPCR method. The HR of these gut markers was calculated using Rstudio-coxph. The associations between these 41 gut markers and age as well as treatment-course were analyzed by heatmap, linear-regression or VIF. Markers for Cox prediction model were selected according to the results of HR, VIF and LASSO regression. Nomogram, calibration curves for nomogram and stratified survival analysis were used to observe the predictive performance of the prediction model and related gut markers. BloUP may be associated with pseudoresponse of immunotherapy, especially in elderly patients. Age (risk**), treatment-type*, treatment-course (protective), clinical-response**, LDH (risk), Amc (risk**), Bvu (protective), Cpe (protective) and Rgn (risk) were recommended as predictors of immunotherapy. For patients with Age> 55 or LDH> 196, the detection of Amc could further predict the prognosis (p = 0.065, p = 0.013). For patients with Age< 55 or LDH< 196, the detection of Bvu could further predict the prognosis (p = 0.007, p = 0.011). For patients with Amc< 0.76 or Bvu > 0.84, longer treatment duration (treatment-course> 10) will significantly improve prognosis (p < 0.001, p = 0.007). AmcLOW and BvuUP marked good immunotherapy responsiveness in melanoma patients, the detection of Amc and Bvu may had potential impacts on immunotherapy strategies. Further detection of gut markers (Amc and Bvu) could better predict patients’ responsiveness to immunotherapy. Revealed the predictive power of 41 gut markers in immunotherapy. Proposed that BloUP may be associated with pseudoresponse in elderly patients. Recommended Amc and Bvu as independent predictive markers of immunotherapy. Proposed that AmcLOW and BvuUP marked good immunotherapy responsiveness in melanoma patients, and the detection of Amc and Bvu may had potential impacts on immunotherapy strategies.Keywords
Funding Information
- Foundation of Sun Yat-sen University Cancer Center for Distinguished Young Scholar (PT04180201)
- National Natural Science Foundation of China (81802725)
This publication has 14 references indexed in Scilit:
- Serum Neutrophil-to-Lymphocyte Ratio and Platelet-to-Lymphocyte Ratio in Prognosticating Immunotherapy EfficacyImmunotherapy, 2020
- Defining tumor resistance to PD-1 pathway blockade: recommendations from the first meeting of the SITC Immunotherapy Resistance TaskforceJournal for ImmunoTherapy of Cancer, 2020
- Prognostic biomarkers for immunotherapy with ipilimumab in metastatic melanomaClinical and Experimental Immunology, 2019
- The gut microbiota influences anticancer immunosurveillance and general healthNature Reviews Clinical Oncology, 2018
- The commensal microbiome is associated with anti–PD-1 efficacy in metastatic melanoma patientsScience, 2018
- Gut microbiome influences efficacy of PD-1–based immunotherapy against epithelial tumorsScience, 2018
- Anticancer immunotherapy by CTLA-4 blockade relies on the gut microbiotaScience, 2015
- Serum Amyloid A As a Prognostic Marker in Melanoma Identified by Proteomic ProfilingJournal of Clinical Oncology, 2009
- High‐Throughput Real‐Time Quantitative Reverse Transcription PCRCurrent Protocols in Molecular Biology, 2006
- Prognostic factors in patients with metastatic malignant melanoma: A multivariate analysisCancer, 1993